Main article

A team of researchers has created a genome-scale map of 26 different cancers, revealing more than 100 genomic sites where DNA from tumors is either missing or abnormally duplicated compared to normal tissues. The study, the largest of its kind, appears in the Feb. 18 issue of Nature.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

March 2010 - Table of Contents

DTTR March 2010 (Full PDF Issue)

IVD Companies, Labs Expand Personalized Medicine Plays

SACGHS Finalizes Recommendations on Gene Patents

Navigenics Raises $18 Million from Investors Including P&G

CancerGuide Diagnostics Partners with LabCorp, Looks to Raise $10.5 Million

Agilent Divests Clinical Diagnostics Business Hycor Biomedical

With Focus on Clinical Toxicology and Forensic Testing, NMS Labs Succeeds as a ‘Lab’s Lab’

Special Focus: Personalized Medicine: Biomarker Could Help Treatment Selection for Rheumatoid Arthritis

Special Focus: Personalized Medicine: Geisinger and TGen Partner for Personalized Medicine Initiative

Special Focus: Personalized Medicine: Researchers Map Genetic Variations Across 26 Cancers

Special Focus: Personalized Medicine: Clarient Launches IHC Test to Aid in Selection of Lung Cancer Therapy

Special Focus: Personalized Medicine: Pfizer and Qiagen to Develop Companion Diagnostic for Brain Tumor Patients

Special Focus: Personalized Medicine: JAMA Study Finds Genetic Links to Lung Cancer Survival

Special Focus: Personalized Medicine: Genomic Health Introduces Colon Cancer Test

Surgical Pathology Topped $1 Billion in Part B Charges in ’08

Myriad Genetics Inks Deal with Mammography Reporting System to Identify Potential Patients

Medco Health Services Acquires DNA Direct

IVD Stocks Slip 4%; Cepheid, Sequenom Join Index

DTTR G2 Insider (March 2010)

Vanderbilt Launches CardioDX Test for Coronary Artery Disease